First patients sought for trial of 'Re-Engineered' immune cells to fight advanced blood cancers
NCT ID NCT05544968
Summary
This is a first-in-human study to test the safety and early effectiveness of a new personalized immunotherapy. It is for adults with certain advanced blood cancers (like Hodgkin lymphoma and others) that have a marker called CD30 and have come back or not responded to at least two prior treatments. Doctors will collect a patient's own immune T-cells, arm them in the lab with a special antibody that targets CD30, and then infuse them back into the patient to try to fight the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.